Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11201 - 11225 of 11777 in total
XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.
Investigational
Matched Description: … XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor …
LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors. In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis.
Investigational
Matched Description: … LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood …
Investigational
BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
Investigational
Matched Description: … BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of …
MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
Investigational
Matched Description: … MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by …
BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
Investigational
Matched Description: … BI-K0376 is a solid. …
Fendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.
Withdrawn
Matched Description: … Fendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction …
Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).
Investigational
Matched Description: … Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability …
JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy).
Investigational
Matched Description: … JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 …
Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).
Investigational
Matched Description: … Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy …
MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Investigational
Matched Description: … MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK …
Praliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (Hfpef)).
Investigational
Matched Description: … Praliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on …
ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.
Investigational
Matched Description: … ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. …
Tilmicosin is a macrolide antibiotic. It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia haemolytica.
Investigational
Vet approved
Matched Description: … Tilmicosin is a macrolide antibiotic. …
Theanine, a precursor of ethylamine, is found in green tea. It is under investigation in clinical trial NCT00291070 (Effects of L-Theanine in Boys With ADHD).
Investigational
Matched Description: … Theanine, a precursor of ethylamine, is found in green tea. …
Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).
Investigational
Matched Description: … Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to …
PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
Investigational
Matched Description: … PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine …
Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Investigational
Matched Description: … Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 …
Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).
Investigational
Matched Description: … Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN- …
Displaying drugs 11201 - 11225 of 11777 in total